380231-99-2

Upstream product

• 205492-38-2 benzyl 3,5-dimethyl-4-(trifluoroacetyl)pyrrole-2-carboxylate 
• 184775-08-4 benzyl 4-(1-hydroxy-2,2,2-trifluoroethyl)-3,5-dimethylpyrrole-2-carboxylate 
• 40236-19-9 benzyl 3,5-dimethylpyrrole-2-carboxylate 
• 546-67-8 lead(IV) tetraacetate 
• 205492-40-6 benzyl (S)-4-(1-hydroxy-2,2,2-trifluoroethyl)-3,5-dimethylpyrrole-2-carboxylate 

Downstream Products

• 220802-69-7 dibenzyl (3S,4'R)-4,3'-dimethyl-3,4'-bis(2,2,2-trifluoro-1-hydroxyethyl)-2,2'-dipyrrylmethane-5,5'-dicarboxylate 
• 220802-72-2 dibenzyl (3S,4'S)-4,3'-dimethyl-3,4'-bis(2,2,2-trifluoro-1-hydroxyethyl)-2,2'-dipyrrylmethane-5,5'-dicarboxylate 

Relevant academic research and scientific papers

Syntheses of chiral fluorine analogs of hematoporphyrin

Four chiral fluorine analogs of hematoporphyrin, (R,R)-, (R,S)-, (S,R)-, and (S,S)-3,8-bis(2,2,2-trifluoro-1-hydroxyethyl)deuteroporphyrins, were synthesized starting from pyrroles with a chiral 2,2,2-trifluoro-1-hydroxyethyl (TFHE) group. This chiral TFHE group was obtained by asymmetric reduction of a trifluoroacetyl group. Among these chiral analogs of hematoporphyrin, the (S,S)-isomer showed higher affinity for cancer cells than other stereoisomers.